Navigation Links
Alemtuzumab in Medical News

Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS

CAMBRIDGE, Mass. and BERLIN /PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer Schering Pharma AG, Germany announce that important, new clinical data will be presented this weekend from two studies regarding alemtuzumab use in patients with multiple sclerosis (MS) at the 23rd Congress of ...

Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018

...s. The report also finds that three additional emerging agents - Biogen Idec's pegylated interferon-beta-1a, Genzyme/Bayer Schering/Bayer HealthCare's alemtuzumab (currently marketed as Campath/MabCampath) and BioMS Medical/Eli Lilly's dirucotide - will also contribute substantially to market growth by providing...

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

...wed limited or no response to both fludarabine and alemtuzumab treatment (fludarabine alemtuzumab refractory) and patients who were refractory to fl...rabine and considered inappropriate candidates for alemtuzumab due to bulky tumor masses (>5 cm) in their lymp...

Researchers find predictive tests and early treatment delay progression of blood cell cancer

...rimental treatments if appropriate. The two targeted therapies studied, alemtuzumab and rituximab, are widely used in advanced-stage CLL. Both are monoclonal a...treatment with chemotherapy and monoclonal antibodies such as rituximab and alemtuzumab can be prescribed, but these treatments do not cure the disease. Researc...

Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients

... Donaldson J, Basu A, et al. 411 Living donor kidney transplants using alemtuzumab pre-conditioning and tacrolimus monotherapy: 5 year experience. Abstra...Rejection characteristics of 200 living donor kidney transplants using alemtuzumab induction and tacrolimus monotherapy: 3 year follow-up. Abstract no. 2...

Multiple Independent Studies Report on Use of Cylex's Immune Cell Function Assay in Postoperative Monitoring of Kidney, Liver, and Heart Transplant Recipients

...D. -- "411 living donor kidney transplants using alemtuzumab pre-conditioning and tacrolismus monotherapy: ... date) of living kidney donor transplants with alemtuzumab preconditioning, including the role of the Cyl... of 200 living donor kidney transplants using alemtuzumab induction and tacrolismus monotherapy" (H. P. Tan,...

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

...erixafor) for stem-cell transplantation and alemtuzumab for multiple sclerosis. Fourth-Quarter 2007 High... clinical trials-particularly the phase 3 study of alemtuzumab for multiple sclerosis; and (3) product launch...l pipeline. The product will join Mozobil and alemtuzumab at the forefront of a development portfolio with ...
Alemtuzumab in Medical Technology

Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy

The results of these studies will be presented during the American Transplant Congress in Boston , MA May 30 - June 3, 2009 COLUMBIA, Md., May 31 /PRNewswire/ -- The results of two large studies presented by researchers from the Starzl Transplant Institute at the University of P...

Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis

Three-Year Analysis Demonstrates Robust, Highly Statistically Significant Treatment Effect of Alemtuzumab Compared to Rebif(R) CAMBRIDGE, Mass., Oct. 15 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ ) today announced that top-line, three-year data from a completed Phase ...

Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis

CAMBRIDGE, Mass., and BERLIN, Sept. 26 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for th...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

...ed a combination of cyclophosphamide, fludarabine, alemtuzumab (Campath) and rituximab (CFAR) as a frontline ther...e of B-Cell Chronic Lymphocytic Leukemia Following alemtuzumab Therapy: Retrospective Study within Various Cytoge...points. Abstract #329 Subcutaneous alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Res...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

...r no response (refractory) to both fludarabine and alemtuzumab treatment (double refractory; DR), and patients wh...rabine and considered inappropriate candidates for alemtuzumab due to bulky tumor masses in their lymph nodes (bu...nts whose disease is refractory to fludarabine and alemtuzumab treatment or patients who are refractory to fludar...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

.... PST) -- Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following alemtuzumab Therapy: Retrospective Study Within Various Cytogenetic Risk Categories ... Poster 329 (December 8, 12:00 p.m. PST) -- Subcutaneous alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial o...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

...rabine and considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. An object...ne and alemtuzumab. In the fludarabine refractory, alemtuzumab inappropriate patient group, an objective response...atients who are refractory to both fludarabine and alemtuzumab and patients who are refractory to fludarabine who...

Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients

...nalysis, while also being prospectively monitored and classified for episodes of infection according to standardized criteria. All patients received alemtuzumab induction and tacrolimus suppression to prevent organ rejection. Results of ImmuKnow assays of CMI were included in the analysis if and when they were...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

...ative study showed significant results in favor of alemtuzumab versus Rebif CAMBRIDGE, Mass. and WAYNE, N.J., Ma... Dr. Coles' presentation showed patients taking alemtuzumab at the high dose experienced an 87 percent reducti...eated with Rebif. At the low dose, patients taking alemtuzumab experienced similar results, with a 72 percent red...
Alemtuzumab in Biological Technology

Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH

...:45AM PST - Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. Poster I-682 - Complement (C) ...

Genzyme Reports Strong Second-Quarter Growth

... -- Genzyme continued to enroll patients in two ongoing Phase 3 trials of alemtuzumab for the treatment of multiple sclerosis. Final, three-year efficacy and safety data from the Phase 2 trial comparing alemtuzumab with Rebif(R) (interferon beta-1a) for the treatment of relapsing-remitting...

Genzyme Reports Strong First-Quarter Growth

...nical trials-particularly the phase 3 study of alemtuzumab for multiple sclerosis. This estimate also re...st data package from Genzyme sponsored studies. alemtuzumab for multiple sclerosis -- Final, three-year effi...d safety data from the Phase 2 trial comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment ...

Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study

...atients who are refractory to both fludarabine and alemtuzumab and 66 fludarabine refractory patients who are considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. An interi...atients who are refractory to both fludarabine and alemtuzumab and patients who are refractory to fludarabine who...
Other Tags
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey has ... They’ve treated over 40,000 patients while carrying out their ... to the Paramus area. , For 2015, the practice ... of top-notch board certified physicians: Christine Milosis MD, Sandra Ugras ... doctors will work tirelessly to carry out The Doctor’s ...
(Date:12/20/2014)... 20, 2014 Atore, Inc, (San Francisco, ... launched first birthday focused portal on December 17th, 2014. ... launched in both US and Japan. , MERRY BIRTHDAY ... http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE is part ... the world. , Features, Choose from thousands of stock ...
(Date:12/20/2014)... Developers of FCPX 3rd ... plugin for Final Cut Pro X entitled TranSlice Volume ... allows users to create hand drawn text animations without ... CEO of Pixel Film Studios. “TranSlice Volume 5 was ... an easy to use interface.” , TranSlice Volume 5 ...
(Date:12/20/2014)... AZ (PRWEB) December 20, 2014 Parker ... professional technicians with years of experience in contractor services ... dedicated contractor services for the homeowners of Arizona. Parker ... team a professional contractor technicians that make customer service ... 1974 in Phoenix Arizona and started with one service ...
(Date:12/19/2014)... Colorado (PRWEB) December 20, 2014 It’s very ... travel is something that is put to the wayside until ... who still have that travel “itch” and that burning desire ... Montrose accommodates families on their journey to Telluride with a ... get visitors to and from the resort, and ensure that ...
Breaking Medicine News(10 mins):Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
Other Contents